Velaglucerase alfa News and Research

RSS
EMA approves Shire's new REPLAGAL manufacturing facility in Lexington

EMA approves Shire's new REPLAGAL manufacturing facility in Lexington

Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting

Shire's Replagal and VPRIV data on Gaucher and Fabry patients presented at ACMG meeting

Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease

Health Canada approves VPRIV enzyme replacement therapy for type 1 Gaucher disease

Shire receives European marketing approval for VPRIV therapy to treat type 1 Gaucher disease

Shire receives European marketing approval for VPRIV therapy to treat type 1 Gaucher disease

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

Shire presents positive data from TKT-025 EXT Phase I/II study for VPRIV in type 1 Gaucher disease patients

VPRIV receives positive opinion from CHMP for treatment of type 1 Gaucher disease

VPRIV receives positive opinion from CHMP for treatment of type 1 Gaucher disease

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Shire announces study results of Vyvanse Capsules CII for treatment of ADHD in adolescents

Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV

Positive data from Shire's Phase III trial of TKT-034 in Type 1 Gaucher disease patients who switched to VPRIV

Shire receives marketing approval from FDA for VPRIV

Shire receives marketing approval from FDA for VPRIV

Gaucher disease: FDA approves VPRIV

Gaucher disease: FDA approves VPRIV

Shire reports total revenues of $3,008 million for 2009

Shire reports total revenues of $3,008 million for 2009

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Positive results from Shire's velaglucerase alfa Phase III study for Type 1 Gaucher disease

Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium

Shire's clinical study results for treatment of Gaucher disease to be presented at LDN World Symposium

Shire submits REPLAGAL BLA with the FDA

Shire submits REPLAGAL BLA with the FDA

Shire submits a MAA for velaglucerase alfa in Europe

Shire submits a MAA for velaglucerase alfa in Europe

Shire receives FDA Priority Review for velaglucerase alfa NDA

Shire receives FDA Priority Review for velaglucerase alfa NDA

Shire announces third quarter 2009 financial results

Shire announces third quarter 2009 financial results

Shire's assistance helps Gaucher patients manage imiglucerase supply shortage

Shire's assistance helps Gaucher patients manage imiglucerase supply shortage

Shire files treatment protocol for Velaglucerase Alfa for Gaucher’s disease

Shire files treatment protocol for Velaglucerase Alfa for Gaucher’s disease